US regulator approves limited use of malaria drugs for virus

510

WASHINGTON, March 30, 2020 (BSS/AFP) – A limited emergency-use
authorization for two antimalarial drugs touted as game-changers by President
Donald Trump has been issued by the US Food and Drug Administration to treat
coronavirus patients.

In a statement published Sunday, the US Department of Health and Human
Services detailed recent donations of medicine to a national stockpile —
including chloroquine and hydroxychloroquine, both being investigated as
potential COVID-19 treatments.

It said the FDA had allowed them “to be distributed and prescribed by
doctors to hospitalized teen and adult patients with COVID-19, as
appropriate, when a clinical trial is not available or feasible.”

Trump said last week that the two drugs could be a “gift from God,” despite
scientists warning against the dangers of overhyping unproven treatments.

Many researchers including Anthony Fauci, the United States’ leading
infectious disease expert, have urged the public to remain cautious until
larger clinical trials validate smaller studies.

Two US medical bodies — the National Institutes of Health and the
Biomedical Advanced Research and Development Authority — are currently
working to plan such trials.

Some in the scientific community fear Trump’s endorsement of the medicines
could create shortages for patients who need them to treat lupus and
rheumatoid arthritis, diseases for which they are approved.

The US has more than 140,000 novel coronavirus cases and 2,489 deaths,
according to a tracker maintained by Johns Hopkins University.